Car-T therapy for hard-to-treat autoimmune diseases
Part of Immune system & allergy clinical trials.
This trial tests whether a patient's own engineered immune cells (called CD19 CAR-T cells) can calm down overactive immune attacks in several autoimmune diseases like lupus, scleroderma, and myositis. It's for people whose disease isn't controlled by standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have a moderate to severe autoimmune disease like lupus, scleroderma, certain forms of vasculitis, myositis, or Sjögren's syndrome that hasn't gotten better with standard medicines.
- Your disease is active despite at least 6 months of standard treatment (for lupus) or 3 months of combination therapy (for other conditions).
- Your organs are working well enough: your blood counts, liver, kidneys, heart, and lungs must be within safe limits for this therapy.
- You agree to use effective birth control during the study and for 2 years after treatment (if you can have children).
- You do not have active cancer, severe infections, or other serious medical conditions that could make this therapy unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using your own immune cells, modified to target and calm the overactive immune system that causes autoimmune diseases. It may help reduce symptoms for conditions like lupus, scleroderma, and others.
This trial tests whether a special immune cell treatment (CD19 CAR-T) can help people with certain severe autoimmune diseases that have not improved with standard therapies. It is a very early study to see if the treatment is safe and effective for conditions like lupus, systemic sclerosis, vasculitis, myositis, or Sjögren's syndrome.
This trial tests a special immune cell therapy (CAR T cells) for people with severe lupus, Sjogren's syndrome, systemic sclerosis, and other autoimmune conditions that haven't improved with standard treatments. The therapy is designed to target and reset the immune system.
This trial tests a new treatment using your own immune cells (called CAR-T cells) designed to target and attack cells that cause autoimmune diseases. It is for people with lupus, Sjögren's syndrome, inflammatory myopathy, scleroderma, Behcet's disease, ANCA-associated vasculitis, IgG4-related disease, antiphospholipid syndrome, or thrombotic thrombocytopenic purpura who have not improved with standard therapies.
This trial uses your own engineered immune cells (CAR-T cells) to treat severe autoimmune diseases like rheumatoid arthritis, lupus, Sjögren's syndrome, or systemic sclerosis that haven't improved with standard medicines. The goal is to see if this treatment can calm the immune system and reduce disease activity.
This study tests a type of immunotherapy called CAR-T cells for people with certain autoimmune diseases like lupus, scleroderma, or myositis. It aims to see if this treatment can help when standard medicines haven't worked well enough.
Hear when a new Autoimmune Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.